Entresto’s effect ‘unclear’ in advanced chronic heart failure: study – Korea Biomedical Review

Novartis’ Entresto (ingredient: sacubitril/valsartan), an angiotensin receptor-neprilysin inhibitor (ARNI), has become the standard therapy for heart failure with reduced ejection fraction (HFrEF).
However, a recent study showed that the treatment did not…

Click here to view the original article.